Lyme Disease & Tick-Borne Co-Infections: Testing & Treatment

Quick answer: Lyme disease — caused by Borrelia burgdorferi and transmitted by black-legged ticks — is the most common vector-borne disease in the United States, with over 476,000 estimated new cases annually (CDC 2022 model). Standard two-tiered serology misses 30–50% of early disseminated Lyme cases. Co-infections including Bartonella, Babesia, Anaplasma, and Ehrlichia are present in 30–50% of tick-bitten patients in endemic regions and require separate testing and treatment. Michigan ranks in the top 15 states for confirmed Lyme disease cases.

Lyme Disease in the Midwest: Michigan’s Emerging Risk

Lyme disease was once considered primarily a Northeast problem — Connecticut, New York, and New England. That geographic distribution has shifted dramatically. The range of Ixodes scapularis (black-legged tick, “deer tick”) has expanded westward and northward with climate change, and Michigan now has established Lyme-endemic counties throughout the western Lower Peninsula, the thumb region, and increasingly the Upper Peninsula.

The Michigan Department of Health and Human Services reports over 1,000 confirmed Lyme cases annually, with the true incidence estimated 10-fold higher (476,000 cases nationwide by CDC modeling versus 63,000 laboratory-confirmed cases in 2022). The expansion of white-tailed deer populations and suburban woodland encroachment have brought Lyme risk into environments previously considered low-risk.

Key Michigan counties with highest confirmed Lyme burden include Allegan, Ottawa, Oceana, Mason, Lake, Osceola, Mecosta, Newaygo, Montcalm, and Clinton counties in the western Lower Peninsula. However, risk exists throughout the state wherever deer, rodents, and sufficient humidity support tick populations — including suburban and even urban parks in the Detroit and Grand Rapids metro areas.

The Borrelia Bacteria: Biology and Life Cycle

Borrelia burgdorferi sensu stricto is the dominant Lyme-causing species in North America, though Borrelia mayonii (recently identified, Upper Midwest) causes a similar but distinct illness. In Europe, B. afzelii and B. garinii predominate, causing different tissue tropism and clinical patterns. Borrelia are spirochetes — corkscrew-shaped gram-negative bacteria with flagella internal to the outer membrane sheath, providing both motility and immune evasion.

The Borrelia life cycle depends on reservoir hosts (white-footed mice, chipmunks, birds) that maintain the bacterium in the tick population. Humans are dead-end accidental hosts — not part of the natural reservoir cycle. Tick attachment of 36–48 hours is generally required for B. burgdorferi transmission, as the bacteria must migrate from the tick midgut to salivary glands during the feeding process. This provides a window for prevention through tick checks and prompt removal.

Borrelia’s remarkable immune evasion mechanisms explain both the difficulty of eliminating infection and the limitation of serological testing. The outer surface protein repertoire (OspA, OspC, VlsE) shifts dynamically during infection and in response to immune pressure, with VlsE variation producing immune escape analogous to HIV variation. Borrelia can survive within host cells (neutrophils, endothelial cells, macrophages), can form biofilm aggregates resistant to antibiotics, and can shift to cystic/persister forms under antibiotic pressure.

Clinical Stages of Lyme Disease

Early Localized (Days 3–30)

Erythema migrans (EM rash) — the classic expanding “bull’s-eye” rash — appears at the site of tick bite in 70–80% of patients. The rash expands over days to weeks, reaching 5 cm or larger. It may be warm and slightly tender but is typically painless and non-pruritic. Critically, only 30–40% of patients recall a tick bite, as nymphal-stage ticks (the primary transmission stage) are the size of a poppy seed and often go unnoticed.

Systemic flu-like symptoms often accompany the EM rash: fatigue, myalgias, arthralgias, headache, and fever — but without respiratory symptoms. Serology (ELISA + Western blot) is typically negative at this stage, as antibody development lags infection by 2–6 weeks. Clinical diagnosis (EM rash in an endemic region) is sufficient to initiate treatment without serological confirmation, per IDSA guidelines.

Early Disseminated (Weeks to Months)

Bacteremia from the primary infection site spreads to joints, heart, and nervous system. Manifestations include: Lyme carditis (heart block, most commonly 1st or 2nd degree, occasionally 3rd degree requiring temporary pacemaker — occurs in 4–10% of untreated patients); Lyme neuroborreliosis (facial palsy/Bell’s palsy in up to 11% of untreated US patients, meningitis, encephalitis, radiculopathy); multiple EM lesions distant from the initial bite; migratory arthralgias and myalgias; and profound fatigue disproportionate to objective findings.

Serological testing at this stage has much better sensitivity (70–80% for IgM, 90–95% for IgG in established disseminated disease), though a significant false-negative rate persists. Patients with neurological Lyme may have CSF analysis (oligoclonal bands, lymphocytic pleocytosis) with CSF-specific Lyme antibody testing providing additional diagnostic sensitivity.

Late Disseminated (Months to Years)

Lyme arthritis is the dominant late manifestation in the US — typically monoarticular or oligoarticular, with the knee the most common site. Lyme arthritis can produce large effusions with marked synovial thickening and be mistaken for septic arthritis, rheumatoid arthritis, or gout. IgG Western blot positivity is highly sensitive at this stage. Lyme encephalopathy — cognitive slowing, memory impairment, psychiatric symptoms — can occur in late neurological Lyme, with corresponding brain SPECT abnormalities in affected patients.

The Serology Problem: Limitations of Standard Testing

The CDC/IDSA-endorsed two-tiered serology (ELISA screening → Western blot confirmation) was designed to maximize specificity (minimize false positives) for surveillance purposes — not to maximize clinical diagnostic sensitivity. The consequence: 30–50% false-negative rate in early localized and early disseminated disease.

The conventional Western blot interpretation criteria (5 of 10 IgG bands OR 2 of 3 IgM bands) was established in 1994 by the Dearborn conference using serum from patients with late-stage Lyme — excluding patients with early-stage disease whose band patterns differ. The criteria were also developed before the discovery of several additional Borrelia antigens that would improve sensitivity. IGeneX (Milpitas, CA) and other specialty laboratories offer more sensitive testing methodologies — including immunoblots with additional antigen bands (31 kDa OspA, 34 kDa OspB, 83/93 kDa), direct antigen testing (Borrelia nanotrap urine antigen), PCR on blood or urine, and multiplex testing for co-infections.

Clinicians should also be aware of the CD57 NK cell panel (Quest Diagnostics) — low CD57+ NK cell counts (<60 cells/μL) are associated with active chronic Lyme disease and co-infections, and normalize with successful treatment. While not a diagnostic test, CD57 can serve as an immune function biomarker useful for monitoring treatment response.

Co-Infections: The Hidden Complexity

Black-legged ticks can transmit multiple pathogens simultaneously. The co-infection rate in tick-bitten patients in Lyme-endemic areas ranges from 2–30% depending on geographic area. Co-infections dramatically complicate clinical presentation and treatment, and standard Lyme treatment (doxycycline) is inadequate or ineffective for several co-infections:

Bartonella: Several species (B. henselae — cat scratch disease, B. quintana — trench fever, and others) are transmitted by ticks, fleas, and cat scratches. Bartonella is an intracellular bacterium infecting endothelial cells, red blood cells, and macrophages. Clinical features that raise suspicion for Bartonella co-infection: stretch marks on the skin (not related to weight change), neuropsychiatric symptoms (anxiety, OCD-like symptoms, mood lability), rash resembling cat scratch disease or linear striations, severe fatigue disproportionate to the infectious load, and encephalopathy. Bartonella requires different antibiotics (azithromycin, rifampin, doxycycline combinations) for adequate treatment. IGeneX, Galaxy Diagnostics, and LabCorp offer Bartonella-specific serology and PCR.

Babesia: A protozoan parasite (B. microti, B. duncani) similar in biology to malaria — infecting and destroying red blood cells. Clinical features: hemolytic anemia, thrombocytopenia, fever with sweats and chills (the “sun going up and down” temperature pattern), fatigue, air hunger, and air hunger out of proportion to oxygen saturation. Babesiosis can be life-threatening in asplenic or immunocompromised patients. Standard Lyme antibiotics do not treat Babesia — requires atovaquone + azithromycin (mild-moderate) or clindamycin + quinine (severe). Testing: peripheral blood smear, PCR, serology (Quest or IGeneX B. microti and B. duncani).

Anaplasmosis and Ehrlichiosis: Anaplasma phagocytophilum (anaplasmosis) and Ehrlichia chaffeensis/ewingii (ehrlichiosis) are obligate intracellular bacteria infecting neutrophils (Anaplasma) or monocytes (Ehrlichia). Clinically: acute febrile illness with leukopenia, thrombocytopenia, elevated liver enzymes, and headache — can be confused with influenza. Can be severe in elderly or immunocompromised patients. Both respond to doxycycline but require prompt treatment — delay increases mortality risk. Testing: PCR (preferred), serology.

Post-Treatment Lyme Disease Syndrome (PTLDS) and “Chronic Lyme”

Approximately 10–20% of patients treated for Lyme disease with standard IDSA-recommended courses report persistent symptoms — fatigue, musculoskeletal pain, cognitive difficulties (“Lyme brain fog”) — lasting 6+ months after documented antibiotic treatment. IDSA classifies this as Post-Treatment Lyme Disease Syndrome (PTLDS) and maintains that evidence does not support extended antibiotic therapy for it. Four RCTs of extended IV and oral antibiotic treatment for PTLDS showed modest improvements that did not significantly exceed placebo in primary endpoints.

The International Lyme and Associated Diseases Society (ILADS) holds that PTLDS in many cases represents persistent active infection requiring longer treatment — citing evidence of Borrelia persistence in animal models after standard antibiotic courses, biofilm formation limiting antibiotic penetration, and the biological plausibility of treatment failure with standard short-course therapy in some patients. The debate between IDSA and ILADS represents one of the most contentious in infectious disease medicine.

The functional medicine perspective acknowledges this controversy while addressing multiple contributing mechanisms in PTLDS patients regardless of the persistence question: immune dysregulation and residual autoimmune activation (some Lyme-associated proteins cross-react with human tissues, triggering post-infectious autoimmunity analogous to rheumatic fever); MCAS triggered by tick salivary proteins and bacterial antigens; mitochondrial dysfunction from the inflammatory response; HPA axis dysregulation from chronic illness stress; and co-infections that may not have been diagnosed or treated. Addressing these mechanisms — even if antibiotic decisions are guided by infectious disease specialists — provides meaningful clinical benefit.

Functional Medicine Approach to Tick-Borne Illness

Beyond antibiotic decisions (which require collaboration with infectious disease specialists), functional medicine addresses the terrain conditions that influence both susceptibility and recovery:

Comprehensive co-infection testing: IGeneX or Galaxy Diagnostics multiplex tick-borne illness panels testing for Borrelia (multiple species), Bartonella, Babesia (microti and duncani), Anaplasma, Ehrlichia, Rickettsia, and RMSF simultaneously — providing the complete co-infection picture that standard single-organism testing misses.

Immune function assessment: CD4/CD8 T cell ratio, NK cell number and activity, lymphocyte transformation testing (LTT for Borrelia — European standard, evaluating T-cell memory response to Borrelia antigens), CD57+ NK cell count, and comprehensive immunoglobulin panel. Immune dysfunction precedes and persists through Lyme disease, and restoration of immune competence is as important as antimicrobial treatment.

Methylation support: MTHFR variants (particularly C677T homozygous) impair detoxification of Borrelia inflammatory neurotoxins and reduce glutathione production, contributing to neurological symptoms and treatment resistance. Methylated B vitamin supplementation (methylfolate, methylcobalamin, P5P) supports both detoxification and immune function in this context.

Biofilm disruption: Borrelia forms biofilm aggregates that dramatically reduce antibiotic penetration. Biofilm disruptors — N-acetylcysteine, lumbrokinase (serrapeptase), stevia leaf extract (in vitro evidence), monolaurin, and ionophore minerals (zinc, copper) — are used in integrative protocols to improve antibiotic access to biofilm-embedded bacteria, though human trial evidence is limited.

Anti-inflammatory and mitochondrial support: Alpha-lipoic acid (crosses blood-brain barrier, anti-inflammatory, mercury/arsenic chelator), glutathione (IV or liposomal), CoQ10 (mitochondrial support), and omega-3 fatty acids address the systemic and neurological inflammation that persists even after successful bacterial clearance.

Herbal antimicrobial adjuncts: Several botanical antimicrobials have in vitro activity against Borrelia and are used in ILADS-aligned protocols: Japanese knotweed (resveratrol-containing, documented Borrelia activity), cat’s claw (Uncaria tomentosa), andrographis, garlic extract (allicin), and black walnut hull. The Buhner herbal protocol is the most systematically organized botanical approach. These are adjuncts to, not replacements for, medical antimicrobial treatment under physician supervision.

Prevention: Tick Bite Avoidance

Primary prevention remains the most effective intervention for Lyme disease. Practical measures with documented efficacy:

DEET-based repellents: 20–30% DEET applied to exposed skin; permethrin applied to clothing, shoes, and gear (not skin). Permethrin-treated clothing provides 99%+ tick bite prevention in controlled studies and retains efficacy through 70 laundry cycles on factory-treated fabrics (Insect Shield, ExOfficio BugsAway).

Tick checks: Immediate full-body tick check after outdoor activity in wooded or grassy areas. Focus on underarm, groin, scalp, behind ears, and around the waistband — preferred nymphal attachment sites. Showering within 2 hours of outdoor exposure reduces attachment time and should be standard practice throughout tick season (April–October in Michigan).

Prophylactic doxycycline: A single 200 mg dose of doxycycline within 72 hours of removing an attached tick (known to be attached 36+ hours) reduces Lyme transmission by 87% (Nadelman et al., 2001, NEJM). This prophylaxis is recommended for patients in endemic areas with confirmed prolonged tick attachment.

FAQs About Lyme Disease and Tick-Borne Illness

Do I have Lyme disease if my test was negative?
Standard ELISA/Western blot serology has a 30–50% false-negative rate in early disseminated Lyme disease and is even less sensitive in early localized Lyme (the first 2–4 weeks). A negative standard test does not exclude Lyme disease in a patient with consistent clinical presentation — particularly the EM rash in an endemic region, which is sufficient for clinical diagnosis per IDSA guidelines without serological confirmation. More sensitive specialty testing (IGeneX, Galaxy Diagnostics) and direct antigen or PCR testing may detect infection missed by standard two-tier serology. Clinical diagnosis based on exposure history, presentation, and geographic risk remains essential when serology is negative but suspicion is high.

How long does Lyme treatment take?
IDSA guidelines recommend: early localized Lyme (EM rash) — 10–21 days of oral doxycycline (100 mg twice daily) or amoxicillin or cefuroxime. Early disseminated Lyme with neurological or cardiac involvement — 14–28 days oral (if mild) or 14–28 days IV ceftriaxone (if moderate-severe). Late Lyme arthritis — 28 days oral doxycycline or amoxicillin. For patients with PTLDS or ILADS-diagnosed chronic/persistent Lyme, treatment duration is individualized based on symptom response, often 2–6 months or longer under specialist supervision. Antibiotic decisions should always involve a physician experienced in tick-borne illness.

Can Lyme disease cause psychiatric symptoms?
Yes — neuropsychiatric manifestations of Lyme and co-infections (particularly Bartonella) are increasingly recognized and include: anxiety (often sudden onset, out-of-proportion, treatment-refractory), OCD-like intrusive thoughts, rage episodes, depression, cognitive slowing, word-finding difficulty, brain fog, psychosis (rare but documented in case reports), and sleep disturbances including vivid nightmares and insomnia. The neuropsychiatric presentation of Bartonella is particularly distinctive — including symptoms resembling bipolar disorder, rage, and treatment-resistant anxiety. PANS/PANDAS (Pediatric Acute-onset Neuropsychiatric Syndrome) in children has been associated with Bartonella, Borrelia, and Streptococcal infections as triggers.

Is there a Lyme disease vaccine?
LYMErix (SmithKline Beecham) was FDA-approved in 1998 and withdrawn in 2002 following a class-action lawsuit alleging arthritis side effects — a controversy never fully resolved, as no causal mechanism was established by the FDA’s safety review. A new Lyme vaccine (VLA15, Pfizer/Valneva) targeting OspA of multiple Borrelia genospecies completed Phase 3 trials (VALOR trial) in 2024 with high efficacy in endemic regions. FDA review for approval is anticipated, representing the first potential Lyme vaccine available in over two decades. For current prevention, tick avoidance and prompt removal remain the primary interventions.

If you are experiencing symptoms consistent with tick-borne illness — fatigue, joint pain, neurological symptoms, or persistent post-infectious syndrome after known or suspected tick exposure — a comprehensive evaluation including advanced tick-borne illness testing and functional medicine assessment of immune function, co-infections, and systemic contributors to symptom persistence provides the most complete diagnostic and therapeutic framework. Contact our office at (810) 206-1402 to schedule a consultation.

Lyme Disease and Tick-Borne Co-Infections: Functional Medicine Diagnosis and Treatment